CABA.US Cabaletta Bio Inc

Healthcare Biotechnology USA Stocks
1.28 USD
Close of Nov 14, 2026
1.18 4.23
Market cap
USD 276M
P/E
-
P/B
1.01x
ROE
-69.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CABA.US undervalued?

Graham number

The Graham number of Cabaletta Bio Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cabaletta Bio Inc fundamental analysis

No fundamental analysis for Cabaletta Bio Inc yet.

Cabaletta Bio Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cabaletta Bio Inc

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, …

Full company profile